title: 14th World Congress on Gastrointestinal Cancer.
authors.forename: Rob
authors.initials: R
authors.lastname: Brierley
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004067:Digestive System Neoplasms / Q000235:genetics / Q000628:therapy*; D042943:Dihydrouracil Dehydrogenase (NADP) / Q000235:genetics / Q000378:metabolism; D000069347:Erlotinib Hydrochloride; D005472:Fluorouracil / Q000009:adverse effects; D005838:Genotype; D006801:Humans; D058990:Molecular Targeted Therapy; D010597:Pharmacogenetics; D010641:Phenotype; D057285:Precision Medicine; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011760:Pyrrolidinones / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D011804:Quinolines / Q000627:therapeutic use; D040262:Receptors, Vascular Endothelial Growth Factor; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use
chemical_list: C551661:ARQ 197; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011760:Pyrrolidinones; D011799:Quinazolines; D011804:Quinolines; D011993:Recombinant Fusion Proteins; C533178:aflibercept; D000069347:Erlotinib Hydrochloride; D042943:Dihydrouracil Dehydrogenase (NADP); D040262:Receptors, Vascular Endothelial Growth Factor; D005472:Fluorouracil